EPIPEN JR adrenaline (epinephrine) 0.15mg/0.3mL injection syringe auto-injector, Alphapharm Pty Ltd (Mylan Australia), CON-341
Product name
EPIPEN JR adrenaline (epinephrine) 0.15mg/0.3mL injection syringe auto-injector
Sponsor name
Alphapharm Pty Ltd (Mylan Australia)
Batches
9KC652
Consent start
Consent no.
CON-341
Standard
The requirements of the United States Pharmacopeia - National Formulary (the USP) monograph Epinephrine Injection
Non-compliance with standard
The batch does not comply with a standard applicable to the goods, namely the
United States Pharmacopeia '“ National Formulary (the USP), in that the
requirement for use of an appropriate manufacturing process has not been met.
Conditions imposed
No more than 10,000 units of the Contaminated Batch can be released for
supply in the month of December, 2019.
No more than 20,000 units of the Contaminated Batch can be supplied in
Australia.
Alphapharm Pty Ltd (Mylan Australia) must keep records relating to the
source and supply of the Contaminated Batch and advise the TGA Medicine
Shortages team (medicine.shortages@health.gov.au) in writing, no less than every
14 calendar days, on the stock levels held by Alphapharm Pty Ltd (Mylan
Australia) and also at the wholesale level, commencing 14 calendar days after
the release for supply of the Contaminated Batch.
A 'Dear Healthcare Professional' letter, with content to be approved by
the TGA, must be provided to every pharmacy prior to or at the time of supply of
the Contaminated Batch. The letter must include
Identification of pralidoxime being present as a contaminant
Reference to the TGA web statement on the matter
Advice that pharmacists can order stock through their usual processes
Confirmation that Epipen (adrenaline (epinephrine) 0.3mg/0.3 mL
auto-injector) AUSTR42978 is unaffected by the contamination
Information about how to report an adverse event to the TGA.
5. Before the Contaminated Batch is released for supply, the 'Dear
Healthcare Professional' letter in paragraph5must be provided, to
The Australasian Society of Clinical Immunology and Allergy
Allergy and Anaphylaxis Australia
The Royal Australian College of General Practitioners
The Pharmacy Guild
The Society of Hospital Pharmacists of Australia
The Pharmaceutical Society of Australia.
6. When unaffected stock is available for supply, Alphapharm Pty Ltd (Mylan
Australia) must notify the TGA Recalls Section at recalls@health.gov.au and the
TGA Medicine Shortages team at medicine.shortages@health.gov.au at least 10
working days prior to release for supply. Supply cannot commence until the TGA
approves a plan for appropriate retrieval of remaining units of the Contaminated
Batch.
Therapeutic product type
Prescription medicines